At Ohio University Heritage College of Osteopathic Medicine, researchers have discovered something counterintuitive: insulin-producing cells in the pancreas don't just need to work—they need to rest. The finding reshapes how scientists understand type 2 diabetes, pointing to a rhythm that healthy bodies maintain but disease erases, and suggesting new pathways for protection.
For decades, researchers knew that beta cells—the insulin factories of the pancreas—release insulin in pulses, roughly every five minutes. They understood that this rhythmic secretion helped the liver respond more effectively to insulin. But what was unclear was whether those pulses also kept the beta cells themselves healthy. "Loss of pulsatile insulin secretion is one of the earliest hallmarks of developing type 2 diabetes, but very little research has explored whether those oscillations are also important for the health of the beta cells themselves," said Craig Nunemaker, Ph.D., the associate professor and Osteopathic Heritage Foundation Ralph S. Licklider, D.O., endowed faculty fellow in diabetes and islet biology who led the study alongside Brian List, Nicholas Whitticar, and Kathryn Corbin.
To answer this question, the research team—publishing their findings in Metabolites—exposed islet cells to high glucose levels mimicking early-stage diabetes. They then introduced a custom-designed system to create rhythmic cycles of activity and rest in these cells. The experiment compared two treatment approaches using a compound called D-mannoheptulose, or MH, which reduces insulin demand. Half the cells received continuous MH treatment; the other half received it in short pulses every few minutes, mimicking the body's natural rhythm.
The results were striking. Cells treated with pulsing MH recovered more normal function than those on continuous treatment. Researchers observed improvements in glucose sensing, calcium signaling, and markers linked to reduced cellular stress—all critical measures of beta-cell health. "This could help guide future research into new ways to protect beta cells during the development of diabetes," Nunemaker reflected on the implications.
What makes this discovery especially valuable is not just what it reveals about diabetes, but what it enables going forward. The Ohio University team developed a new laboratory platform to control rhythmic activity in beta cells with precision. This tool opens doors to better understanding exactly how diabetes damages insulin-producing cells—and crucially, how to protect them. The platform could eventually test any cells that naturally oscillate, from pituitary cells that release growth hormone to stomach cells that produce ghrelin, the hunger hormone.
For the millions living with or at risk of type 2 diabetes, the implications are hopeful. If beta cells can stay healthier longer by maintaining their natural rhythmic cycles, future therapies might slow or even prevent the disease's progression. The research suggests that the answer isn't always to push cells harder—sometimes, it's about giving them permission to rest. In that simple insight lies the potential for treatments that work with the body's own wisdom rather than against it.